Welcome to our dedicated page for Vericel news (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel stock.
Vericel Corporation develops and markets advanced therapies for sports medicine and severe burn care, with U.S. commercial products that include MACI, Epicel and NexoBrid. News about VCEL commonly covers financial results, MACI procedure and surgeon activity, burn care revenue trends, and manufacturing capacity for cell therapy products.
Company updates also include regulatory and operational milestones, such as FDA approval of commercial MACI manufacturing at Vericel's advanced therapy facility, as well as BARDA-supported procurement and development activities for NexoBrid. The recurring themes center on commercialization, specialty biologics supply, product access and development within Vericel's cellular therapy portfolio.
Vericel Corporation (NASDAQ:VCEL) announced that its President and CEO, Nick Colangelo, will present an overview of the company at the Canaccord Genuity Virtual Musculoskeletal Conference. The presentation is scheduled for May 20, 2021, at 9:30 a.m. Eastern Time. Interested parties can access a live webcast through the Investor Relations section of the Vericel website.
Vericel specializes in advanced therapies for sports medicine and severe burn care, offering innovative products such as MACI® and Epicel®.
Vericel Corporation (NASDAQ:VCEL) reported a 30% increase in total net revenue for Q1 2021, reaching $34.6 million, up from $26.7 million in Q1 2020. Notable revenue contributions include $23.8 million from MACI® and $9.8 million from Epicel®. The gross margin improved to 66%, and adjusted EBITDA rose to $4.6 million. Full-year revenue guidance is raised to $165-$168 million.
Vericel ended Q1 with $110 million in cash and no debt, indicating a strong financial position.
Vericel Corporation (NASDAQ:VCEL) has scheduled a conference call on May 5, 2021, at 8:30 am (EDT) to discuss its first-quarter 2021 financial results. The earnings call can be accessed live on the company's website. Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing MACI® and Epicel® cell therapy products in the U.S. The company also holds commercial rights to NexoBrid®, aimed at severe thermal burns. For further details, investors can visit the Investor Relations section of the Vericel website.
Vericel Corporation (NASDAQ:VCEL) will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 4:30 p.m. ET. The presentation will be led by President and CEO Nick Colangelo. A live webcast of the event will be available on Vericel's Investor Relations website. Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing MACI® and Epicel®, with exclusive rights for NexoBrid® in North America.
Vericel Corporation (NASDAQ:VCEL) announced that President and CEO Nick Colangelo will present a company overview at the Oppenheimer 31st Annual Healthcare Conference. The virtual presentation is scheduled for March 17, 2021, at 10:00 a.m. Eastern Time. A live webcast will be available on the Investor Relations section of the Vericel website. Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing cell therapy products MACI® and Epicel® in the U.S., and holds exclusive rights to NexoBrid® for severe thermal burn treatment.
Vericel Corporation (NASDAQ:VCEL) announced that CFO Joe Mara will present at the H.C. Wainwright Virtual Global Life Sciences Conference. The presentation will provide a company overview and will be accessible via webcast on March 9, 2021, at 7:00 a.m. ET. Vericel specializes in advanced therapies for sports medicine and severe burns, marketing two major products: MACI® for cartilage repair and Epicel® for skin replacement in burn patients. The company also holds rights to NexoBrid®, aimed at severe thermal burn debridement.
Vericel Corporation (NASDAQ:VCEL) reported strong financial results for Q4 2020, with total net revenue increasing 15% to $45.2 million. Key highlights include MACI® revenue of $34.7 million and Epicel® revenue of $9.6 million, contributing to a gross margin of 74%. The company achieved a net income of $12.2 million ($0.25 per share), up from $9.5 million in Q4 2019. For full-year 2021, total net revenue is expected to grow 30%-32%, aiming for approximately $161 to $164 million. Analysts will discuss these results in today's conference call at 8:30 AM ET.
Vericel Corporation (NASDAQ:VCEL) announced that its President and CEO, Nick Colangelo, will present a company overview at the SVB Leerink 10th Annual Global Healthcare Conference. The virtual presentation is scheduled for February 25, 2021, at 10:00 a.m. Eastern Time. A live webcast will be accessible through the Investor Relations section of the Vericel website. Vericel specializes in advanced therapies in sports medicine and severe burn care, marketing products like MACI® and Epicel®.
Vericel Corporation (NASDAQ:VCEL) announced that its President and CEO, Nick Colangelo, along with CFO Joe Mara, will engage in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2021, at 3:00 PM ET. A live webcast of the event will be accessible through the Investor Relations section of Vericel's website. The company leads in advanced therapies for sports medicine and severe burn care, marketing products like MACI® and Epicel®.
Vericel Corporation (NASDAQ:VCEL) announced the termination of its shareholder rights agreement, or "poison pill," which was set to expire on August 15, 2021. This action accelerates the expiration to February 11, 2021, with no required action from shareholders. CEO Nick Colangelo emphasized that this termination aligns with the company's goal of enhancing governance policies for shareholders.
Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing products such as MACI® and Epicel® for cartilage repair and skin replacement, respectively.